Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 31

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 31
---
 the following annual committee fees:

| Committee                                     |     | Chair |     |         |     | Other  
 Member |     |         |
| Audit Committee                               |     |       |     | $20,000 |     |        |     | $10,000 |
| Compensation Committee                        |     |       |     | $15,000 |     |        |     |  $7,500 |
| Nominating and Corporate Governance Committee |     |       |     | $10,000 |     |        |     |  $5,000 |
| Research and Development Committee            |     |       |     | $20,000 |     |        |     | $10,000 |

For fiscal year 2024, the annual committee fees for non-chair members of the Audit Committee were increased to $10,000 (from $9,000 with respect to fiscal year 2023) and for non-chair members of the Compensation Committee were increased to $7,500 (from $6,000 with respect to fiscal year 2023). The Board also approved payment of an annual committee fee to members of the newly-formed Research and Development Committee of $20,000 for chair members and $10,000 for non-chair members. Director and committee fees are paid in quarterly installments and pro-rated as necessary for partial year service.

Each of our non-employee directors is awarded annually, on the first business day following each annual general meeting of the shareholders, a nonqualified stock option to acquire a specified number of the Company’s ordinary shares. After considering input from the independent consultant engaged by the Compensation Committee, the number of shares subject to the annual option awards was set at 15,000 shares (consistent with the annual director stock option grants for fiscal year 2023). These options vest on the earlier of the first anniversary of the grant date or the day of the next annual general meeting of shareholders (subject to continuous service as a director until such vesting date, except in the event of certain terminations of service) and have a ten-year term.

In connection with Mr. Welch’s initial appointment as Chair Designate to the Board in February 2024, after considering input from the Compensation Committee’s independent consultant, he was granted a nonqualified stock option to acquire 132,000 of the Company’s ordinary shares. This option vests in equal annual installments over five years following the grant date (subject to Mr. Welch’s continuous service as a director until each such vesting date, except in the event